IF: 1.578
Cite Score:
1.45
THOMSON REUTERS - SCOPUS

Serum Insulin-Like Growth Factor-I and Tumor Size in Patients with Metastatic Liver Cancer

AUTHORS

Mohsen Masoodi 1 , * , Rahim Aghazadeh 2 , Mohammad Hossein Somi 3 , Ahmad Shavakhi 4 , Abbas Arjmand Shabestari 2 , Mohammad Reza Zali 2

AUTHORS INFORMATION

1 Department of Internal Medicine, Hormozgan University of Medical Sciences, masoodi47@yahoo.com, Hormozgan, IR.Iran

2 Research Center for Gastroenterology & Liver Diseases (RCGLD), Shaheed Beheshti University of Medical Sciences, Tehran, IR.Iran

3 Tabriz Liver and Gastrointestinal Diseases Research Center (LGDRC), Tabriz University of Medical Sciences, Azarbayejan-e-Sharghi, IR.Iran

4 Isfahan University of Medical Sciences, Isfahan, IR.Iran

How to Cite: Masoodi M, Aghazadeh R, Somi M, Shavakhi A, Shabestari A, et al. Serum Insulin-Like Growth Factor-I and Tumor Size in Patients with Metastatic Liver Cancer, Hepat Mon. Online ahead of Print ; 8(3):179-183.

ARTICLE INFORMATION

Hepatitis Monthly: 8 (3); 179-183
Article Type: Research Article
Received: November 20, 2007
Accepted: August 26, 2008

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background and Aims: Insulin-like growth factor-I (IGF-1) is a liver-derived humoral factor, which has important anabolic and metabolic actions. Low serum concentrations of IGF-1 have been reported in patients with chronic liver disease, especially cirrhosis and hepatocellular carcinoma and metastatic liver cancer. The aim of our study was to evaluate any possible relationship between intensity of liver metastases on serum IGF-1 concentrations.

Methods:  Serum IGF-1 were measured by ELIZA (III) in10 patients with uninodular or multinodular liver metastases and extension |£50% (group A) and 10 patients with multinodular or massive liver metastases and extension > 50% (group B) of liver size without liver failure.

Results: Serum IGF-1 concentration was significantly lower in the more sever metastatic group (group B) than the less sever metastatic group (group A) (121.40 ± 52.08 vs. 210.30 ± 42.59 ng/ml, respectively; P < 0.001).

Conclusions: Our findings suggest that the states of serum IGF-1 levels in patients with metastatic liver cancer may be a helpful finding for determining the severity of metastasis to the liver.

Keywords

IGF-1 Metastatic Liver Cancer Computed Tomography

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: